Sanofi launches diabetes drug Soliqua in India

Soliqua is indicated as a treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.

Living with type 2 diabetes could get complicated and burdensome.

A large category of patients on multiple medications have to deal with weight gain, hypoglycemia and multiple injection pricks, even as they struggle to keep their blood sugar under control.

The need of the hour is to help them reach and maintain optimal glycemic (blood sugar) control, keeping such worries at bay.

Soliqua simplifies these complexities by offering patients a sustained blood-sugar control, all day, in a simple, once-daily injection that can seamlessly fit into their lifestyle and help them break through the complexity of their diabetes management.

Cyrus Aibara Head – Diabetes Business Unit, Sanofi (India), “Over 100 million Indians are living with type 2 diabetes and its complexities. Of these, over 60% people are living with uncontrolled blood sugar levels and have a higher risk of developing complications, despite being on treatment including multiple OADs (oral anti-diabetics) over a long period of time.

“The inclusion of Soliqua to our comprehensive diabetes portfolio (orals and injectables) eases therapy initiation, which helps those prescribed, keep their blood sugar in control more effectively.”

Dr. Shalini Menon Country Medical Lead, Sanofi (India) said, “Despite the advances in diabetes care, many people living with type 2 diabetes are unable to reach their sugar goals. Fear of hypoglycemia, weight gain and multiple injections can be barriers to effective treatment with insulins.

“In clinical trials, the combination injectable Soliqua has demonstrated effective sugar control, without weight gain and with lower risk of hypoglycemia, compared to twice daily premix insulins.

“Soliqua is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.

“This global innovation is now accessible at a nominal therapy cost of INR 1850 per pen, enabling wider access to patients living with type 2 diabetes mellitus.”